TScan Therapeutics, Inc.
A biopharmaceutical company developing T cell therapies for the treatment of cancer. The company uses its proprietary platform, TargetScan, to pinpoint T cell receptor (TCR) targets that respond effectively to immunotherapy, develop genetically engineered therapies, and use ReceptorScan technology to diversify treatments. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 161 |
Founded | 2018 |
Financials | |
|---|---|
Market Capitalization | 356.30M |
Revenue | 14.81M |
Operating Income | -102.09M |
Operating Margin | -689.22% |
Net Income | -96.80M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4799 / 5373 |
Sector : Healthcare | 887 / 1144 |
Industry : Biotechnology | 455 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3232 / 5565 |
Sector : Healthcare | 494 / 1182 |
Industry : Biotechnology | 239 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4732 / 5436 |
Sector : Healthcare | 885 / 1164 |
Industry : Biotechnology | 455 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3693 / 5330 |
Sector : Healthcare | 508 / 1174 |
Industry : Biotechnology | 170 / 667 |